Have a feature idea you'd love to see implemented?
Let us know!
SCYX Scynexis Inc
Price (delayed)
$1.48
Market cap
$56.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.74
Enterprise value
$45.03M
SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly
Highlights
The company's net income has shrunk by 180% YoY and by 135% QoQ
The company's EPS has shrunk by 179% YoY and by 135% QoQ
Key stats
What are the main financial stats of SCYX
Market
Valuations
Earnings
Shares outstanding
37.86M
Market cap
$56.03M
Enterprise value
$45.03M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.93
Price to sales (P/S)
7.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.66
Revenue
$9.67M
EBIT
-$33.89M
EBITDA
-$33.61M
Free cash flow
-$10.18M
Per share
Balance sheet
Liquidity
EPS
-$0.74
Free cash flow per share
-$0.21
Book value per share
$1.6
Revenue per share
$0.2
TBVPS
$2.22
Total assets
$107.81M
Total liabilities
$47.4M
Debt
$15.54M
Equity
$60.41M
Working capital
$69.35M
Debt to equity
0.26
Current ratio
3.75
Quick ratio
3.7
Net debt/EBITDA
0.33
Margins
Efficiency
Dividend
EBITDA margin
-347.7%
Gross margin
-55.8%
Net margin
-366.1%
Operating margin
-537%
Return on assets
-28.1%
Return on equity
-47.3%
Return on invested capital
-40.3%
Return on capital employed
-41%
Return on sales
-350.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SCYX stock price
How has the Scynexis stock price performed over time
Intraday
-0.67%
1 week
3.5%
1 month
10.45%
1 year
-30.52%
YTD
-33.63%
QTD
-0.67%
Financial performance
How have Scynexis's revenue and profit performed over time
Revenue
$9.67M
Gross profit
-$5.4M
Operating income
-$51.91M
Net income
-$35.39M
Gross margin
-55.8%
Net margin
-366.1%
SCYX's operating income has shrunk by 184% YoY and by 170% QoQ
The company's net income has shrunk by 180% YoY and by 135% QoQ
Scynexis's gross margin has shrunk by 163% QoQ and by 156% YoY
The gross profit has shrunk by 104% QoQ and by 104% YoY
Growth
What is Scynexis's growth rate over time
Valuation
What is Scynexis stock price valuation
P/E
N/A
P/B
0.93
P/S
7.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.66
The company's EPS has shrunk by 179% YoY and by 135% QoQ
SCYX's price to book (P/B) is 80% lower than its 5-year quarterly average of 4.7 and 7% lower than its last 4 quarters average of 1.0
The equity has declined by 35% year-on-year and by 18% since the previous quarter
The P/S is 149% higher than the last 4 quarters average of 3.0 but 94% lower than the 5-year quarterly average of 124.3
Scynexis's revenue has shrunk by 93% QoQ and by 93% YoY
Efficiency
How efficient is Scynexis business performance
Scynexis's return on assets has shrunk by 167% YoY and by 138% QoQ
SCYX's return on invested capital has dropped by 158% year-on-year and by 135% since the previous quarter
The return on equity has dropped by 139% since the previous quarter and by 122% year-on-year
Dividends
What is SCYX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SCYX.
Financial health
How did Scynexis financials performed over time
The total assets is 127% more than the total liabilities
The current ratio has plunged by 58% YoY
Scynexis's quick ratio has shrunk by 55% YoY
Scynexis's debt is 74% less than its equity
The company's debt to equity has surged by 63% YoY and by 24% QoQ
The equity has declined by 35% year-on-year and by 18% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.